
Cristcot: Specializing in innovative drug delivery systems for gastroenterology, neurology, and pain management.
Cristcot was founded with the mission to innovate drug delivery systems in the fields of gastroenterology, neurology, and pain management. The company's vision is to address significant gaps in disease management that are often overlooked by other pharmaceutical firms. Cristcot's flagship product, currently in Phase 3 clinical trials, aims to halt acute flares in ulcerative colitis, highlighting its focus on gastroenterology. The company also has a pipeline of future products targeting similar therapeutic areas.
Notable affiliated individuals and investors in Cristcot include key figures from the pharmaceutical industry, although specific names are not publicly disclosed. The company's significant achievement includes advancing its ulcerative colitis treatment to Phase 3 clinical trials, indicating promising efficacy and safety results. Cristcot's impact lies in its strategic approach to addressing unmet medical needs in specialized fields, potentially improving the quality of life for patients with chronic conditions.

Crinetics Pharmaceuticals
crinetics.com

Cotera

Celtaxsys
celtaxsys.com

CytoAgents
cytoagents.com

Crititech
crititech.com
Control Delivery Systems

Neurocarrus
neurocarrus.com
Critical Biologics

NeuroTherapeutics Pharma

Precision IBD

Cara Therapeutics

Cogentus Pharmaceuticals

CraniUS
craniusmed.com

Cytogel Pharma
cytogelpharma.com

Theracos
theracos.com
Companies similar to Cristcot include Crinetics Pharmaceuticals, Cotera, Celtaxsys and CytoAgents.
Cristcot was founded in 2008.
Cristcot's headquarters is located in Concord, CA, US.
Cristcot's most recent funding round was for $13.7M (USD) in October 2019.
As of Oct 23, 2019, Cristcot has raised a total of $22.5M (USD).
Cristcot has 11 employees as of Feb 5, 2024.